DAFTAR PUSTAKA
1. Indonesia Society of Intensive Care Unit. [cited 2012 Sept 23]. Available
from http://www.perdici.org/
2. Dewoto, H.R, et al. Buku Farmakologi dan Terapi edisi 5 : Antikoagulan,
Antitrombotik, Trombolitik dan Hemostatik. Jakarta: Departemen
Farmakologi dan Terapeutik FKUI, 2009: 804-810
3. Adi Satrio. Pengaruh pemberian heparin subkutan dan heparin intravena
sebagai profilaksis thrombosis vena dalam (TVD) terhadap PTT/K dan
jumlah trombosit pada pasien di ICU RSUP DR. Kariadi Semarang. 2013. [cited 2013 February 28]. Available from eprints.undip.ac.id/
4. Sam Schulman. Hemorrhagic Complications of Anticoagulant and
Thrombolytic Treatment American College of Chest Physicians Evidence
Based Clinical Practice Guidelines (8th Edition). (CHEST 2008;
133:257S–298S). [cited 2012 Sept 29]. Available from http://publications.chestnet.org
5. Maureen A Smythe. Use of the Activated Partial Thromboplastin Time for
Heparin Monitoring. (Am J Clin Pathol 2001;115:148-155). [cited 2013
February 28]. Available from http://ajcp.ascpjournals.org
6. Syed Reza. Assessment of Bleeding Risk in Patients on Antiplatelet and
Anticoagulant Therapy. 2012. [cited 2013 February 28]. Available from
http://www.priory.com/medicine/bleeding_risk.htm
7. Ridzky Djanuar. Perbandingan pemberian heparin intravena dan subkutan
8. Riskiawan Angga. Pengaruh pemberian heparin intravena sebagai
profilaksis Deep Vein Thrombosis terhadap nilai PPT dan PTTK. 2012. [cited 2013 Jun 28]. Available from eprints.undip.ac.id/
9. Jack Hirsh, Theodore E. Warkentin, et al. Heparin and Low-Molecular-
Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing,
Monitoring, Efficacy, and Safety (CHEST 2004; 126:188S–20). [cited 2012 Sept 28]. Available from http://publications.chestnet.org
10.Jack Hirsh, Kenneth A. Bauer, et al. Parenteral Anticoagulants. American
College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) (CHEST 2008; 133:141S–159S). [cited 2012 Sept 28]. Available from http://publications.chestnet.org
11.Levitan N, Dowlati A, et al. Rates of initial and recurrent thromboembolic
disease among patients with malignancy versus those without malignancy.
Risk analysis using Medicare claims data. 1999 (Sep);78(5):285–91. [cited 2013 May 28]. Available from www.ncbi.nlm.nih.gov/pubmed/10499070
12.Goitom Hagos, M.D. Lower Extremity Deep Vein Thrombosis among
Intensive Care Patients in Orotta, National Referral Hospital, Asmara,
Eritrea, JEMA; 2008. ) [cited 2013 May 28]. Available from
www.ajol.info/index.php/jema/.../40736
13.Michael K Gould. LMWH compare with UHF for treatment of Deep
Acute Vein Thrombosis – A cost effectiveness analysis. (Ann Intern Med.2001;130:789-799). [cited 2012 Sept 26]. Available from
http://publications.chestnet.org
14.Theodore E. Warkentin. Prevalence and Risk of Preexisting
Heparin-Induced Thrombocytopenia Antibodies in Patients With Acute VTE.
(CHEST 2011; 140(2):366–373). [cited 2012 Sept 30]. Available from http://publications.chestnet.org
15.Gennari C, Martini G. Secondary osteoporosis. 10(3):214-24 1998 Jun.
1]. [cited 2012 Sept 28]. Available from
http://www.ncbi.nlm.nih.gov/pubmed
16.M.R. Caballeroand M. Allergy to heparin: A new vitrodiagnostic
technique. Allergy and Immunopathology 2003;31(6):324-8. Departament
Allergy and Immunology, Faculty of Medicine, University de Navarra,
Pamplona. Spain. [cited 2012 Oct 1]. [cited 2012 Sept 28]. Available from
http://www.ncbi.nlm.nih.gov/pubmed
17.Ronald, Reagan. Anticoagulant Management Program and Guidelines.
UCLA Medical Center. 2008. [cited 2012 Sept 28]. Available from http://medres.med.ucla.edu/guidelines
18.Peterson D, Harward S, Lawson J.H. Anticoagulation strategies for
venous thromboembolism. Perspect Vasc Surg Endovasc Ther 2009; 21;125. ) [cited 2012 Sept 28]. Available from
http://www.ncbi.nlm.nih.gov/pubmed
19.Suharti C. Dasar-DasarHemostasis.Dalam :Aru W Sundarudkk. (editor)
Buku Ajar Ilmu Penyakit Dalam.Edisi keempat.Jakarta. Pusat Penerbitan
Departemen Ilmu Penyakit Dalam. Edisi keempat. Jakarta. Pusat
Penerbitan Departemen Ilmu Penyakit Dalam FKUI.2006
20.Wijanda Hidajati S. Stabilitas sampel plasma sitrat selama penyimpanan
untuk pemeriksaan APTT dan PT. (Dept Patologi Klinik 2012).[cited 2013
February 28]. Available from http://penelitian.unair.ac.id/artikel_dosen
21.Kitchen S. Prothrombine time and INR. 2010. [cited 2013 Jun 28].
Available from http://pathology.vcu.edu/clinical/coag/PT%20INR.Pdf
22.Roger S. Riley. Activated Partial Thromboplastin Time (APTT). April
2005. [cited 2013 February 28]. Available from http://pathology.vcu.edu
23.Agnelli G, Caprini JA. The Prophylaxis of Venous Thrombosis in Patients
with Cancer Undergoing Major Abdominal Surgery: emerging options. J Surg Oncol 2007;96:265-272. [cited 2013 February 28]. Available from
24.Gottfried EL and Adachi MM, "Prothrombin Time and Activated Partial
Thromboplastin Time Can Be Performed on the First Tube,"Am J Clin Pathol, 1997, 107(6):681-3. [cited 2013 Jun 28]. Available from http://ncbi.nlm.nih.gov/pubmed/9169665
25.Sukrisman L. Trombosis Vena Dalam dan Emboli Paru dalam Ilmu
Penyakit Dalam. Penerbit FKUI. Jakarta, 2006; 802-03
26.William H. Geerts. Prevention of Venous Thromboembolism. (CHEST
No Register Diagnosis JK Usia L.R BB Rute Jenis 1 C264762 Post CABG Wanita 59 6 49 IV UHF 2 C272181 Post OP DVR Laki-laki 24 7 65 IV UHF 3 C285953 Post Laparatomi Laki-laki 52 7 75 IV UHF 4 C276475 Post Histerektomi Wanita 46 5 53 IV UHF 5 C283471 Post Laparatomi Laki-laki 71 4 50 IV UHF 6 C283444 Post Laparatomi Wanita 28 7 70 IV UHF 7 C277275 Post OP DVR Wanita 17 4 37 IV UHF 8 C072726 Post Craniotomi Wanita 52 4 50 IV UHF 9 C284326 Post Laparatomi Wanita 23 7 50 IV UHF 10 C263161 Post OP URS Laki-laki 61 6 80 IV UHF 11 C273627 Post TPM Laki-laki 70 4 60 IV UHF 12 C284590
Post Fiksasi
Interna Laki-laki 50 5 45 IV UHF
13 C287341 Post Thoracotomi Laki-laki 29 6 70 IV UHF 14 C274874 Post Laparatomi Wanita 46 4 50 IV UHF 15 C285394 Post Craniotomi Wanita 31 5 45 IV UHF 16 C279894 Post Laparatomi Wanita 47 6 50 IV UHF 17 C282255 Post Thoracotomi Laki-laki 63 4 50 IV UHF 18 C278454 Post CABG Laki-laki 53 4 65 IV UHF 19 C222772
Post OP Kista
Ovarii Wanita 43 4 50 IV UHF
20 C264314
Post OP Tumor
Ovarii Wanita 41 7 40 IV UHF
21 C279975 Post Thoracotomi Laki-laki 44 4 65 IV UHF 22 C295047 Post Sectio Wanita 18 4 45 IV UHF 23 C285953 Post Laparatomi Laki-laki 52 7 50 IV UHF 24 C273019
Post
L.H Dosis skor sebelum skor sesudah
PTo PTc APTTo APTTc PT1 PTc APTT1 APTTc 6 500 13.7 13.7 38.9 31.9 13.9 13.3 44.6 31.9 7 500 18.1 13.7 42 32.3 19 14.4 45.4 31.9 4 500 14.8 13.6 39.5 31.5 13.3 13.4 37.1 31.5 5 500 15.2 14.1 41.2 31.8 16.3 14 40.1 31.9 4 500 15.6 14.5 35.1 32.5 14.9 14.5 41.5 32.5 7 500 16.7 10.6 40.5 34.9 18.3 10.6 39 35 4 500 17.8 13.8 45.2 32.6 17.3 13.8 43.5 32.6 4 500 10.6 10.9 43.2 33.3 10.8 10.6 45.6 34.1 7 500 13.9 14.5 40.7 32.5 15.7 10.2 43.1 33.5 6 500 15.9 14.5 42.3 31.8 17 14.4 47.1 32 4 500 15.4 13.1 41.8 31.7 18.3 13.4 43.8 32.1 5 500 18.1 14.5 39.5 32.5 21.2 14.5 41.3 32.5 6 500 11.7 11.2 37.6 33.2 15 12.5 40.4 33.2 4 500 15.2 13.7 40.3 29 15 13.7 38.6 29 5 500 10.7 10.5 37.6 30.5 13.8 14.1 36.8 29.3 4 500 15.3 14.1 40.7 31.4 14.2 14.1 41.5 29.8 4 500 14.5 13.8 38.6 29.5 14.1 14.3 39.6 29.3 5 500 16.5 13.7 38.1 29 15.8 10.9 40.3 34.1 4 500 13 11.3 35.1 31.4 12 14 34.4 33.8 5 500 15.5 13.7 32.7 29 14.2 10.8 37.4 31.6 4 500 14.2 13.7 40.1 29 14 13.7 37.1 29 4 500 10 11.6 40.9 34.6 13 11.6 39.1 34.5 5 500 14.3 14.4 41.7 30.3 16.5 14.4 45.1 30.3 7 500 13.2 12.6 37.4 34 14 12.5 41.9 33.8 7 500 11.9 11 39.2 32 13.5 10.9 38.9 31.5 5 500 13.4 14.4 36 30.3 13.8 10.1 38.3 32
5 500 14.2 12.9 37.5 34 14 13 41 33.5
skor sebelum keluar ICU PTx PTc APTTx APTTc 17.9 14.1 47.4 31.7 21.1 12.1 53 31.7 16.1 13.7 39.7 32.3 18.5 13.8 43.8 31.6 16.9 14.3 45.8 32.5 20.4 10.7 44.4 37.2 18 10.9 46.3 33.9 10.5 10.7 43.1 33.9 18 10.1 46.4 34.2 19.2 14.5 51 31.9 17.9 13.2 51.6 31.9 24.6 10.1 43 32.2 15.1 12.1 42 33.2 15.1 13.8 44 29.3 20.3 14.2 38.7 29.3 19 13.8 40.7 29.5 13.1 19.4 42 34.4
15.2 11 44.4 34
11.9 11 39.5 33.4 18.9 11.2 46.3 33.8 13.5 13.8 40.2 29 17.1 11.5 39 34.5 19 13.7 49.5 29.8 18.4 12.5 44 33.4
18 11.2 46 31.3
19.7 13.7 48.2 29.8 18.5 13.5 43.9 32.7 19.2 10.5 42.6 34.5 19.2 14 40.8 29.6 21.5 10.4 47.6 35.1
PTo PT sebelum mendapat heparin APTTo APPT sebelum mendapat heparin PT1 PT sesudah mendapat heparin APTT1 APTT sesudah mendapat heparin PTx PT sebelum keluar ICU
Output SPSS
Descriptives
Descriptives
pasien keluar I CU
APTT sebelum pasien keluar I CU
Tests of Normal ity pasien keluar ICU APTT sebelum pasien keluar ICU
St at ist ic df Sig. St at ist ic df Sig.
Kolmogorov -Smirnova Shapiro-Wilk
This is a lower bound of the true signif icance. *.
Lillief ors Signif icance Correction a.
Paired Samples Statistics
14.4467 30 2.06810 .37758
15.1400 30 2.20041 .40174
PT sebelum
-.69333 1.44650 .26409 -1.23347 -.15320 -2.625 29 .014
PT sebelum menerima Heparin - PT setelah menerima Heparin Paired Dif f erences
t df Sig. (2-tailed)
Paired Samples Statistics
15.1400 30 2.20041 .40174
17.7267 30 2.95331 .53920
PT setelah menerima Heparin PT sebelum pasien keluar ICU Pair
1
Mean N Std. Dev iat ion
Paired Samples Test
-2.58667 2.30856 .42148 -3.44870 -1.72463 -6.137 29 .000
PT setelah menerima Heparin - PT sebelum pasien keluar ICU Pair Paired Dif f erences
t df Sig. (2-tailed)
Paired Samples Statistics
39.1533 30 2.84905 .52016
40.6167 30 3.14161 .57358
APTT sebelum
-1.46333 2.55079 .46571 -2.41581 -.51085 -3.142 29 .004
APTT sebelum menerima Heparin - APTT setelah menerima Heparin Paired Dif f erences
t df Sig. (2-tailed)
Paired Samples Statistics
40.6167 30 3.14161 .57358
44.4967 30 3.78695 .69140
APTT setelah menerima Heparin APTT sebelum pasien keluar ICU Pair
-3.88000 2.78622 .50869 -4.92039 -2.83961 -7.627 29 .000
APTT setelah menerima Heparin - APTT sebelum pasien keluar I CU Pair Paired Dif f erences
